Clinical Research & Reference Standard Compendium
Ipamorelin Spray - Scientific Literature
I. Abstract & Overview
Ipamorelin is a synthetic pentapeptide agonist at the ghrelin receptor, first described by Raun and colleagues in 1998 under the designation of the first selective growth hormone secretagogue. Its significance is comparative rather than novel: earlier secretagogues such as GHRP-6 released growth hormone but simultaneously elevated corticotropin, cortisol and prolactin, whereas Ipamorelin produced growth hormone release in laboratory models without that accompanying response. The receptor it targets was itself cloned by Howard and colleagues in 1996, following pharmacological work by Bowers and colleagues on the earlier hexapeptides. The molecule incorporates two D-configured residues and a naphthylalanine that does not occur in natural proteins, features that confer resistance to peptidase attack. Research Use Only (RUO).
II. Chemical Specifications
| Molecular Formula | C38H49N9O5 |
|---|---|
| Molar Mass | 711.9 g/mol (PubChem CID 9831659) |
| CAS Registry Number | 170851-70-4 |
| Amino Acid Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 residues; two D-configured residues plus 2-naphthylalanine, C-terminal amide) |
III. Mechanism & Cellular Signaling Pathways
Ipamorelin activates the ghrelin receptor on pituitary somatotroph cells, and the signaling route is calcium-driven rather than cAMP-driven. Receptor engagement couples through Gq to phospholipase C, which cleaves membrane phosphoinositides into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting calcium transient triggers fusion of growth hormone secretory vesicles with the plasma membrane. Research shows this mechanism is entirely separate from the GHRH receptor route used by Sermorelin and Tesamorelin, which is why the two classes can be run as controls for one another in the same experiment. What distinguishes Ipamorelin within the ghrelin receptor class is selectivity of downstream output: laboratory investigations report growth hormone release without the corticotropin, cortisol and prolactin elevation characteristic of GHRP-6.
IV. Primary Research Directions
- **Secretagogue Selectivity Panels:** Raun and colleagues (1998) report growth hormone release without the corticotropin, cortisol and prolactin response GHRP-6 produces, measured in the same samples.
- **Calcium Mobilization Assays:** Research shows Gq-coupled signaling in cells stably expressing the ghrelin receptor, read as intracellular calcium flux rather than cAMP accumulation.
- **Cross-Class Mechanism Controls:** Laboratory investigations pair it with Sermorelin or Tesamorelin to separate the calcium-driven ghrelin route from the cAMP-driven GHRH route in one experiment.
- **Growth Hormone Release Assays:** Studies indicate increased growth hormone secretion into culture medium, quantified by immunoassay in primary rat pituitary cell preparations.
- **Peptidase Stability Profiling:** Research shows the two D-configured residues confer resistance to enzymatic cleavage, measurable by comparing degradation rates against an all-L analog.
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
- Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). 'A receptor in pituitary and hypothalamus that functions in growth hormone release.' Science, 273(5277), 974-977. DOI: 10.1126/science.273.5277.974 | PMID: 8688086
- Bowers, C. Y., Sartor, A. O., Reynolds, G. A., et al. (1991). 'On the actions of the growth hormone-releasing hexapeptide, GHRP.' Endocrinology, 128(4), 2027-2035. DOI: 10.1210/endo-128-4-2027 | PMID: 2004615
Ipamorelin Spray
Abstract & Overview
Ipamorelin is a synthetic pentapeptide agonist at the ghrelin receptor, first described by Raun and colleagues in 1998 under the designation of the first selective growth hormone secretagogue. Its significance is comparative rather than novel: earlier secretagogues such as GHRP-6 released growth hormone but simultaneously elevated corticotropin, cortisol and prolactin, whereas Ipamorelin produced growth hormone release in laboratory models without that accompanying response. The receptor it targets was itself cloned by Howard and colleagues in 1996, following pharmacological work by Bowers and colleagues on the earlier hexapeptides. The molecule incorporates two D-configured residues and a naphthylalanine that does not occur in natural proteins, features that confer resistance to peptidase attack. Research Use Only (RUO).
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Ipamorelin Spray) | 5.20 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 5.20 minutes represents the active compound (Ipamorelin Spray). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Ipamorelin activates the ghrelin receptor on pituitary somatotroph cells, and the signaling route is calcium-driven rather than cAMP-driven. Receptor engagement couples through Gq to phospholipase C, which cleaves membrane phosphoinositides into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting calcium transient triggers fusion of growth hormone secretory vesicles with the plasma membrane. Research shows this mechanism is entirely separate from the GHRH receptor route used by Sermorelin and Tesamorelin, which is why the two classes can be run as controls for one another in the same experiment. What distinguishes Ipamorelin within the ghrelin receptor class is selectivity of downstream output: laboratory investigations report growth hormone release without the corticotropin, cortisol and prolactin elevation characteristic of GHRP-6.
Primary Research Directions
**Secretagogue Selectivity Panels:** Raun and colleagues (1998) report growth hormone release without the corticotropin, cortisol and prolactin response GHRP-6 produces, measured in the same samples.
**Calcium Mobilization Assays:** Research shows Gq-coupled signaling in cells stably expressing the ghrelin receptor, read as intracellular calcium flux rather than cAMP accumulation.
**Cross-Class Mechanism Controls:** Laboratory investigations pair it with Sermorelin or Tesamorelin to separate the calcium-driven ghrelin route from the cAMP-driven GHRH route in one experiment.
**Growth Hormone Release Assays:** Studies indicate increased growth hormone secretion into culture medium, quantified by immunoassay in primary rat pituitary cell preparations.
**Peptidase Stability Profiling:** Research shows the two D-configured residues confer resistance to enzymatic cleavage, measurable by comparing degradation rates against an all-L analog.
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). 'Ipamorelin, the first selective growth hormone secretagogue.' European Journal of Endocrinology, 139(5), 552-561. DOI: 10.1530/eje.0.1390552 | PMID: 9849822
Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). 'A receptor in pituitary and hypothalamus that functions in growth hormone release.' Science, 273(5277), 974-977. DOI: 10.1126/science.273.5277.974 | PMID: 8688086
Bowers, C. Y., Sartor, A. O., Reynolds, G. A., et al. (1991). 'On the actions of the growth hormone-releasing hexapeptide, GHRP.' Endocrinology, 128(4), 2027-2035. DOI: 10.1210/endo-128-4-2027 | PMID: 2004615
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
